Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition

References

• Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39 - 51; http://dx.doi.org/10.1056/NEJMra043186; PMID: 17611206
   PubMed Web of Science ®Google Scholar
• Wu WJ, Dokmanovic M. Trastuzumab. In Encyclopedia of Cancer, M. Schwab, ed. Berlin, Heidelberg, Germany: SpringerReference; Springer-Verlag; 2009. http://dx.doi.org/10.1007/SpringerReference_177618.
   Google Scholar
• Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61:4744 - 9; PMID: 11406546
   PubMed Web of Science ®Google Scholar
• Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18:977 - 84; http://dx.doi.org/10.1093/annonc/mdl475; PMID: 17229773
   PubMed Web of Science ®Google Scholar
• Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009; 15:429 - 40; http://dx.doi.org/10.1016/j.ccr.2009.03.020; PMID: 19411071
   PubMed Web of Science ®Google Scholar
• Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, Ullrich A, Shepard HM. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1991; 1:72 - 82; PMID: 1688187
   PubMedGoogle Scholar
• Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA, Lipkowitz S. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001; 61:4892 - 900; PMID: 11406568
   PubMed Web of Science ®Google Scholar
• Valabrega G, Montemurro F, Sarotto I, Petrelli A, Rubini P, Tacchetti C, Aglietta M, Comoglio PM, Giordano S. TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. Oncogene 2005; 24:3002 - 10; http://dx.doi.org/10.1038/sj.onc.1208478; PMID: 15735715
   PubMed Web of Science ®Google Scholar
• Austin CD, De Mazière AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, Scheller RH. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004; 15:5268 - 82; http://dx.doi.org/10.1091/mbc.E04-07-0591; PMID: 15385631
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, Hirsch DS, Shen Y, Wu WJ. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer. Mol Cancer Ther 2009; 8:1557 - 69; http://dx.doi.org/10.1158/1535-7163.MCT-09-0140; PMID: 19509242
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, Shen Y, Bonacci TM, Hirsch DS, Wu WJ. Trastuzumab regulates IGFBP-2 and IGFBP-3 to mediate growth inhibition: implications for the development of predictive biomarkers for trastuzumab resistance. Mol Cancer Ther 2011; 10:917 - 28; http://dx.doi.org/10.1158/1535-7163.MCT-10-0980; PMID: 21487052
   PubMed Web of Science ®Google Scholar
• Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6:117 - 27; http://dx.doi.org/10.1016/j.ccr.2004.06.022; PMID: 15324695
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010; 177:1647 - 56; http://dx.doi.org/10.2353/ajpath.2010.090885; PMID: 20813970
   PubMed Web of Science ®Google Scholar
• Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006; 8:215; http://dx.doi.org/10.1186/bcr1612; PMID: 17096862
   PubMed Web of Science ®Google Scholar
• Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003; 11:495 - 505; http://dx.doi.org/10.1016/S1097-2765(03)00048-0; PMID: 12620236
   PubMed Web of Science ®Google Scholar
• Scott GK, Dodson JM, Montgomery PA, Johnson RM, Sarup JC, Wong WL, Ullrich A, Shepard HM, Benz CC. p185HER2 signal transduction in breast cancer cells. J Biol Chem 1991; 266:14300 - 5; PMID: 1677643
   PubMed Web of Science ®Google Scholar
• Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 2005; 304:604 - 19; http://dx.doi.org/10.1016/j.yexcr.2004.12.008; PMID: 15748904
   PubMed Web of Science ®Google Scholar
• Ginestier C, Adélaïde J, Gonçalvès A, Repellini L, Sircoulomb F, Letessier A, Finetti P, Geneix J, Charafe-Jauffret E, Bertucci F, et al. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene 2007; 26:7163 - 9; http://dx.doi.org/10.1038/sj.onc.1210528; PMID: 17525746
   PubMed Web of Science ®Google Scholar
• Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, Kong A. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol 2010; 8:e1000563; http://dx.doi.org/10.1371/journal.pbio.1000563; PMID: 21203579
   PubMed Web of Science ®Google Scholar
• Hudelist G, Köstler WJ, Czerwenka K, Kubista E, Attems J, Müller R, Gschwantler-Kaulich D, Manavi M, Huber I, Hoschützky H, et al. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Int J Cancer 2006; 118:1126 - 34; http://dx.doi.org/10.1002/ijc.21492; PMID: 16161043
   PubMed Web of Science ®Google Scholar
• Dankort D, Jeyabalan N, Jones N, Dumont DJ, Muller WJ. Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins. J Biol Chem 2001; 276:38921 - 8; http://dx.doi.org/10.1074/jbc.M106239200; PMID: 11500516
   PubMed Web of Science ®Google Scholar
• Dankort DL, Wang Z, Blackmore V, Moran MF, Muller WJ. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Mol Cell Biol 1997; 17:5410 - 25; PMID: 9271418
   PubMed Web of Science ®Google Scholar
• Akiyama T, Matsuda S, Namba Y, Saito T, Toyoshima K, Yamamoto T. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain. Mol Cell Biol 1991; 11:833 - 42; PMID: 1671296
   PubMed Web of Science ®Google Scholar
• Kim S, Zagozdzon R, Meisler A, Baleja JD, Fu Y, Avraham S, Avraham H. Csk homologous kinase (CHK) and ErbB-2 interactions are directly coupled with CHK negative growth regulatory function in breast cancer. J Biol Chem 2002; 277:36465 - 70; http://dx.doi.org/10.1074/jbc.M206018200; PMID: 12122014
   PubMed Web of Science ®Google Scholar
• Chong YP, Chan AS, Chan KC, Williamson NA, Lerner EC, Smithgall TE, Bjorge JD, Fujita DJ, Purcell AW, Scholz G, et al. C-terminal Src kinase-homologous kinase (CHK), a unique inhibitor inactivating multiple active conformations of Src family tyrosine kinases. J Biol Chem 2006; 281:32988 - 99; http://dx.doi.org/10.1074/jbc.M602951200; PMID: 16959780
   PubMed Web of Science ®Google Scholar
• Zrihan-Licht S, Deng B, Yarden Y, McShan G, Keydar I, Avraham H. Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation. J Biol Chem 1998; 273:4065 - 72; http://dx.doi.org/10.1074/jbc.273.7.4065; PMID: 9461599
   PubMed Web of Science ®Google Scholar
• Bougeret C, Jiang S, Keydar I, Avraham H. Functional analysis of Csk and CHK kinases in breast cancer cells. J Biol Chem 2001; 276:33711 - 20; http://dx.doi.org/10.1074/jbc.M104209200; PMID: 11445575
   PubMed Web of Science ®Google Scholar
• Boerner JL, Biscardi JS, Silva CM, Parsons SJ. Transactivating agonists of the EGF receptor require Tyr 845 phosphorylation for induction of DNA synthesis. Mol Carcinog 2005; 44:262 - 73; http://dx.doi.org/10.1002/mc.20138; PMID: 16167350
   PubMed Web of Science ®Google Scholar
• Okabayashi Y, Kido Y, Okutani T, Sugimoto Y, Sakaguchi K, Kasuga M. Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells. J Biol Chem 1994; 269:18674 - 8; PMID: 8034616
   PubMed Web of Science ®Google Scholar
• Klapper LN, Waterman H, Sela M, Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 2000; 60:3384 - 8; PMID: 10910043
   PubMed Web of Science ®Google Scholar
• Mueller KL, Powell K, Madden JM, Eblen ST, Boerner JL. EGFR tyrosine 845 phosphorylation–dependent proliferation and transformation of breast cancer cells require activation of p38 MAPK. Transl Oncol 2012; 5:327 - 34; http://dx.doi.org/10.1593/tlo.12163; PMID: 23066441
   PubMed Web of Science ®Google Scholar
• Radhakrishnan Y, Shen X, Maile LA, Xi G, Clemmons DR. IGF-I stimulates cooperative interaction between the IGF-I receptor and CSK homologous kinase that regulates SHPS-1 phosphorylation in vascular smooth muscle cells. Mol Endocrinol 2011; 25:1636 - 49; http://dx.doi.org/10.1210/me.2011-0035; PMID: 21799000
   PubMed Web of Science ®Google Scholar
• Thymiakou E, Episkopou V. Detection of signaling effector-complexes downstream of bmp4 using PLA, a proximity ligation assay. J Vis Exp 2011; 49:e2631; PMID: 21403637
   PubMedGoogle Scholar
• Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K, Isola J. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004; 3:1585 - 92; PMID: 15634652
   PubMed Web of Science ®Google Scholar
• Lai HW, Chien SY, Kuo SJ, Tseng LM, Lin HY, Chi CW, Chen DR. The potential utility of curcumin in the treatment of HER-2-overexpressed breast cancer: an in vitro and In vivo comparison study with herceptin. Evid Based Complement Alternat Med 2012; 2012:486568; http://dx.doi.org/10.1155/2012/486568; PMID: 21876713
   PubMed Web of Science ®Google Scholar
• Graham J, Muhsin M, Kirkpatrick P. Cetuximab. Nat Rev Drug Discov 2004; 3:549 - 50; http://dx.doi.org/10.1038/nrd1445; PMID: 15272498
   PubMed Web of Science ®Google Scholar
• Doody JF, Wang Y, Patel SN, Joynes C, Lee SP, Gerlak J, Rolser RL, Li Y, Steiner P, Bassi R, et al. Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. Mol Cancer Ther 2007; 6:2642 - 51; http://dx.doi.org/10.1158/1535-7163.MCT-06-0506; PMID: 17913857
   PubMed Web of Science ®Google Scholar
• Kumar R, Shepard HM, Mendelsohn J. Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Mol Cell Biol 1991; 11:979 - 86; PMID: 1671297
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719 - 26; http://dx.doi.org/10.1200/JCO.20.3.719; PMID: 11821453
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, Wu WJ. Trastuzumab-resistance and breast cancer. In Breast Cancer-carcinogenesis, cell growth and signalling pathways. Prof.M. Gunduz, ed. Rijeka, Croatia: In Tech; 2011. 171-204p.
   Google Scholar
• Hirsch DS, Shen Y, Wu WJ. Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42. Cancer Res 2006; 66:3523 - 30; http://dx.doi.org/10.1158/0008-5472.CAN-05-1547; PMID: 16585176
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al, American Society of Clinical Oncology/College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131:18 - 43; PMID: 19548375
   PubMed Web of Science ®Google Scholar